vs

Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $207.8M, roughly 1.1× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 19.4%, a 38.0% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $34.8M).

IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

IDYA vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.1× larger
ORGO
$225.6M
$207.8M
IDYA
Higher net margin
IDYA
IDYA
38.0% more per $
IDYA
57.4%
19.4%
ORGO
More free cash flow
IDYA
IDYA
$107.4M more FCF
IDYA
$142.2M
$34.8M
ORGO

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
IDYA
IDYA
ORGO
ORGO
Revenue
$207.8M
$225.6M
Net Profit
$119.2M
$43.7M
Gross Margin
Operating Margin
52.2%
28.1%
Net Margin
57.4%
19.4%
Revenue YoY
78.1%
Net Profit YoY
330.1%
469.5%
EPS (diluted)
$1.33
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IDYA
IDYA
ORGO
ORGO
Q4 25
$225.6M
Q3 25
$207.8M
$150.9M
Q2 25
$101.0M
Q1 25
$86.7M
Q4 24
$126.7M
Q3 24
$0
$115.2M
Q2 24
$0
$130.2M
Q1 24
$0
$110.0M
Net Profit
IDYA
IDYA
ORGO
ORGO
Q4 25
$43.7M
Q3 25
$119.2M
$21.6M
Q2 25
$-9.4M
Q1 25
$-18.8M
Q4 24
$7.7M
Q3 24
$-51.8M
$12.3M
Q2 24
$-52.8M
$-17.0M
Q1 24
$-39.6M
$-2.1M
Gross Margin
IDYA
IDYA
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Q1 24
73.9%
Operating Margin
IDYA
IDYA
ORGO
ORGO
Q4 25
28.1%
Q3 25
52.2%
13.7%
Q2 25
-12.5%
Q1 25
-30.9%
Q4 24
8.1%
Q3 24
5.4%
Q2 24
-10.7%
Q1 24
-3.5%
Net Margin
IDYA
IDYA
ORGO
ORGO
Q4 25
19.4%
Q3 25
57.4%
14.3%
Q2 25
-9.3%
Q1 25
-21.7%
Q4 24
6.1%
Q3 24
10.7%
Q2 24
-13.1%
Q1 24
-1.9%
EPS (diluted)
IDYA
IDYA
ORGO
ORGO
Q4 25
$0.31
Q3 25
$1.33
$0.11
Q2 25
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$-0.60
$0.09
Q2 24
$-0.68
$-0.13
Q1 24
$-0.53
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IDYA
IDYA
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$786.9M
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.1B
$300.1M
Total Assets
$1.2B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IDYA
IDYA
ORGO
ORGO
Q4 25
$93.7M
Q3 25
$786.9M
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$920.0M
$94.3M
Q2 24
$701.7M
$89.9M
Q1 24
$698.8M
$88.6M
Total Debt
IDYA
IDYA
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
IDYA
IDYA
ORGO
ORGO
Q4 25
$300.1M
Q3 25
$1.1B
$255.1M
Q2 25
$233.2M
Q1 25
$242.9M
Q4 24
$262.9M
Q3 24
$1.2B
$278.5M
Q2 24
$931.7M
$263.5M
Q1 24
$935.3M
$278.0M
Total Assets
IDYA
IDYA
ORGO
ORGO
Q4 25
$598.7M
Q3 25
$1.2B
$509.8M
Q2 25
$461.1M
Q1 25
$467.4M
Q4 24
$497.9M
Q3 24
$1.2B
$446.3M
Q2 24
$973.7M
$443.2M
Q1 24
$961.5M
$458.5M
Debt / Equity
IDYA
IDYA
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IDYA
IDYA
ORGO
ORGO
Operating Cash FlowLast quarter
$142.2M
$39.4M
Free Cash FlowOCF − Capex
$142.2M
$34.8M
FCF MarginFCF / Revenue
68.4%
15.4%
Capex IntensityCapex / Revenue
0.0%
2.1%
Cash ConversionOCF / Net Profit
1.19×
0.90×
TTM Free Cash FlowTrailing 4 quarters
$13.5M
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IDYA
IDYA
ORGO
ORGO
Q4 25
$39.4M
Q3 25
$142.2M
$3.1M
Q2 25
$-32.9M
Q1 25
$-19.9M
Q4 24
$10.9M
Q3 24
$-49.2M
$8.7M
Q2 24
$-32.9M
$4.7M
Q1 24
$-43.8M
$-10.2M
Free Cash Flow
IDYA
IDYA
ORGO
ORGO
Q4 25
$34.8M
Q3 25
$142.2M
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$-49.7M
$6.1M
Q2 24
$-33.9M
$2.9M
Q1 24
$-45.1M
$-12.4M
FCF Margin
IDYA
IDYA
ORGO
ORGO
Q4 25
15.4%
Q3 25
68.4%
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Q1 24
-11.3%
Capex Intensity
IDYA
IDYA
ORGO
ORGO
Q4 25
2.1%
Q3 25
0.0%
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Q1 24
2.0%
Cash Conversion
IDYA
IDYA
ORGO
ORGO
Q4 25
0.90×
Q3 25
1.19×
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons